Stryker Corporation (SYK)
NYSE · Healthcare · Medical Devices
$285.22+3.55%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $109B
- P/E (trailing)
- 29.6
- Forward P/E
- 17.1
- Dividend yield
- 1.2%
- 52-week range
- $267.00 – $392.55
- 52-week change
- −25.41%
- EPS (trailing)
- $9.65
- Analyst rating
- 1.7 Buy
- Next earnings
- Oct 29, 2026
Fiscal year to Dec 2025
- Revenue
- $25.1B (+11.16%)
- Net income
- $3.2B
- Operating margin
- 19.5%
- Diluted EPS
- $8.40
- Free cash flow
- $4.3B
From the company’s annual report on SEC EDGAR.
About Stryker Corporation
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications.
Headquarters: Portage, United States · 56,000 employees · stryker.com